Breakthrough antiviral compound slashes poultry deaths in groundbreaking trials

Mangoceuticals, Inc. has released promising new data on its antiviral compound, MGX-0024. The treatment, designed for poultry, demonstrated a dramatic reduction in respiratory disease-related deaths during recent trials. Early results suggest it could become a valuable tool for commercial farms in the near future.

Field trials of MGX-0024 involved around 29,000 broiler chickens across three independent studies. In these tests, the compound eliminated respiratory-related mortality entirely—an outcome far exceeding expectations, as untreated flocks typically face a 50% death rate. The formulation, classified as GRAS (Generally Recognised as Safe), consists of polyphenols and zinc, delivered through standard drinking-water systems.

A separate controlled study, conducted at ICAR-NIHSAD under strict BSL-3 conditions, focused on the highly pathogenic H5N1 strain. Results showed a 60% drop in mortality among treated chicks, alongside a notable delay in the time to death compared to untreated controls. This lab work was sponsored by Vipragen Biosciences, while the broader field research was funded by Mangoceuticals in partnership with Solice International and IntraMont Technologies.

The company has already begun commercial discussions to prepare for a limited rollout of MGX-0024 in select markets. Intellectual property protections are in place, including U.S. Patent No. 11,517,523 and corresponding patents in multiple countries. However, no regulatory bodies outside the U.S. have yet initiated formal approval processes for the compound.

Further studies are planned, including multi-farm trials in India. Mangoceuticals and IntraMont are also exploring grant funding through agencies like the USDA, BARDA, and their international counterparts. The company acknowledges that while current findings appear robust, they remain preliminary and require larger-scale validation and regulatory review.

MGX-0024's early success in reducing poultry mortality has sparked interest in its commercial potential. If further trials and regulatory steps progress as planned, the treatment could soon be available to farmers in key markets. For now, the focus remains on expanding research and securing necessary approvals.